Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 3 | 7 |
| List of Tables | 6 | 1 |
| List of Figures | 7 | 3 |
| Biosimilars Approval Pathways in the US and Europe Introduction | 10 | 1 |
| GBI Research Report Guidance | 10 | 1 |
| Biosimilars Approval Pathways in the US and Europe Market Overview | 11 | 15 |
| Overview of the Biopharmaceutical Industry | 11 | 8 |
| Biosimilars and their Significance | 19 | 3 |
| Comparison of Biosimilars with Generics | 22 | 2 |
| Biopharmaceutical Manufacturing Process | 24 | 2 |
| Biosimilars Approval Pathways in the US and Europe Market Characterization | 26 | 19 |
| Global Biosimilar Market Size and Forecast | 26 | 1 |
| The US Biosimilars Market Size and Forecast | 27 | 1 |
| Europe Biosimilar Market Size and Forecast | 28 | 2 |
| Japan Biosimilars Market Size and Forecasts | 30 | 1 |
| Market Forecasts for Biosimilars | 31 | 1 |
| Human Growth Hormone (hGH) Biosimilars Markets | 31 | 2 |
| Erythropoietin (EPO) Biosimilars Markets | 33 | 2 |
| Granulocyte Colony Stimulating Factor (G-CSF) Biosimilars Markets | 35 | 2 |
| Opportunity Analysis | 37 | 1 |
| Interferon alfa Biosimilars | 37 | 1 |
| Interferon beta Biosimilars | 38 | 2 |
| Insulin and Insulin Analogs Biosimilars | 40 | 2 |
| TNF alfa Inhibitor Biosimilars | 42 | 1 |
| Biosimilars for Monoclonal Antibodies against Cancer | 43 | 2 |
| Biosimilars Approval Pathways in the US and Europe Industry Dynamics | 45 | 6 |
| Key Success Factors in the Biosimilar Industry | 45 | 1 |
| Long Term Strategy | 45 | 1 |
| Sound Financial Structure | 46 | 1 |
| Comprehensive Competitive Intelligence | 46 | 1 |
| Biomanufacturing Competencies | 46 | 1 |
| Clinical Development and Regulatory Expertise | 46 | 1 |
| Marketing, Sales and Distribution Capabilities | 46 | 1 |
| Participants in the Biosimilar Industry | 47 | 1 |
| Suppliers | 48 | 1 |
| Clinical Trial Capability Providers | 48 | 1 |
| Manufacturing Capacity Providers | 48 | 1 |
| Media and Reagents Providers | 48 | 1 |
| Innovators | 49 | 1 |
| Stakeholders | 49 | 1 |
| Regulators | 49 | 1 |
| Payers | 49 | 1 |
| Physicians | 50 | 1 |
| Patients and Patient Groups | 50 | 1 |
| Biosimilars Approval Pathways in the US and Europe Drivers and Restraints | 51 | 8 |
| Drivers | 52 | 1 |
| Need to Cut Healthcare Costs in Developed Economies | 52 | 2 |
| Lower Development Costs and Regulatory Costs Compared to a New Biologic Drug | 54 | 1 |
| Lower Overall Cost of Treatment Using Biosimilar Drugs Compared to Biologics | 55 | 1 |
| Patent Expiry for Blockbuster Biologics | 55 | 1 |
| Increasing Uptake of Biologic Drugs | 56 | 1 |
| More Profitable than Generic Drugs | 56 | 1 |
| Restraints | 56 | 1 |
| Absence of Automatic Substitution | 56 | 1 |
| Higher Development and Manufacturing Costs Compared to Generics | 57 | 1 |
| High Entry Barriers | 58 | 1 |
| Threat from Second Generation Biologic Drugs | 58 | 1 |
| Patent Protection Around Biologic Drugs | 58 | 1 |
| Biosimilars Approval Pathways in the US and Europe Regulatory Landscape | 59 | 38 |
| Regulatory Landscape in the US | 60 | 1 |
| Regulatory Framework for Biopharmaceutical Industry | 60 | 2 |
| Evolution of Regulatory Pathways for Biosimilars | 62 | 3 |
| BPCIA and the Pathway for Approval of Biosimilar Products | 65 | 1 |
| Biosimilarity and Interchangeability | 65 | 1 |
| FDA Guidelines for Approval and Regulation of Biosimilars | 65 | 1 |
| Data Requirement | 65 | 1 |
| Market and Data Exclusivity | 66 | 1 |
| Patent Dispute Resolution Procedure | 66 | 2 |
| Notice of Commercial Marketing | 68 | 1 |
| Closure of the FD&C 505(b) approval pathway for biologics | 69 | 1 |
| Substitution is a Decision Taken at Local Level | 69 | 1 |
| FDA s Public Meeting on Biosimilars | 70 | 1 |
| Data requirement to Demonstrate Biosimilarity | 71 | 1 |
| The Standard for Interchangeability | 71 | 1 |
| Naming for Biosimilars | 71 | 1 |
| Extrapolation | 71 | 1 |
| Foreign Studies | 71 | 1 |
| Other Issues | 71 | 1 |
| Drivers and Barriers | 72 | 1 |
| Regulatory Landscape in Europe | 73 | 1 |
| Regulatory Framework for Biopharmaceutical Industry | 73 | 1 |
| Evolution of Regulatory Pathways for Biosimilars | 74 | 1 |
| Current Position on Biosimilars | 75 | 1 |
| Overarching Guidelines | 76 | 1 |
| Quality Guidelines | 77 | 1 |
| Non Clinical and Clinical Guidelines | 77 | 1 |
| Annexes Product Specific Guidelines | 77 | 1 |
| Post Authorization Requirements | 78 | 1 |
| Data Exclusivity Period | 79 | 1 |
| What does this mean to the Biosimilar Industry? | 80 | 1 |
| The Bolar Type Provision | 80 | 1 |
| The Comparability Exercise | 81 | 1 |
| Biosimilars Approvals and Applications | 82 | 2 |
| EMEA Guidelines for Biosimilar mAb | 84 | 1 |
| Issues Facing the European Biosimilars Industry | 84 | 1 |
| Naming | 84 | 1 |
| Labeling | 85 | 1 |
| Substitution/Interchangeability | 85 | 1 |
| Pharmacovigilance | 85 | 1 |
| Drivers for the European Biosimilars Market | 85 | 1 |
| Patent Expiry of Key Biologic Drugs Will Boost the Market Potential | 86 | 1 |
| Biosimilars Will Be Widely Accepted by Payers as Means to Reduce Rising Healthcare Costs | 86 | 1 |
| Leading Pharma Companies Eye Biosimilars as an Area of Growth | 86 | 1 |
| Biosimilar Manufacturers from Low Cost Emerging Countries Will Drive Market Expansion | 86 | 1 |
| Barriers for the European Biosimilars Market | 86 | 1 |
| Substitution Still Remains a Contentious Issue in Many European Countries | 86 | 1 |
| Barriers to Entry Remain High Due to a Complex and High Cost Manufacturing Process | 86 | 1 |
| Trade-off Between Patient Safety and Healthcare Costs Will Resist the Acceptance of Biosimilars | 87 | 1 |
| Country Analysis The UK | 87 | 1 |
| Structure of the Healthcare System | 87 | 1 |
| Pricing and Reimbursement Mechanisms | 87 | 1 |
| Drivers and Barriers for Biosimilars | 88 | 1 |
| Country Analysis Germany | 88 | 1 |
| Structure of the Healthcare System | 88 | 1 |
| Pricing and Reimbursement Mechanisms | 89 | 1 |
| Drivers and Barriers for Biosimilars | 89 | 1 |
| Country Analysis France | 90 | 1 |
| Structure of the Healthcare System | 90 | 1 |
| Pricing and Reimbursement Mechanisms | 90 | 1 |
| Drivers and Barriers for Biosimilars | 91 | 1 |
| Country Analysis Spain | 91 | 1 |
| Structure of the Healthcare System | 91 | 1 |
| Pricing and Reimbursement Mechanisms | 91 | 1 |
| Drivers and Barriers for Biosimilars | 92 | 1 |
| Country Analysis Italy | 93 | 1 |
| Structure of the Healthcare System | 93 | 1 |
| Pricing and Reimbursement Mechanisms | 93 | 1 |
| Drivers and Barriers for Biosimilars | 93 | 1 |
| Regulatory Landscape in Japan | 94 | 1 |
| Regulatory Framework for Biopharmaceutical Industry | 94 | 1 |
| Evolution of Regulatory Pathways for Biosimilars | 94 | 1 |
| Current Position on Biosimilars | 95 | 1 |
| Approved Biosimilars | 95 | 1 |
| Drivers and Barriers | 96 | 1 |
| Biosimilars Approval Pathways in the US and Europe Competitive Landscape | 97 | 25 |
| Profiles of Major Biosimilar Players | 97 | 1 |
| Sandoz | 97 | 1 |
| Approved Biosimilar Products: | 98 | 1 |
| Financial Performance | 99 | 1 |
| Teva Pharmaceuticals Ltd | 100 | 1 |
| Approved Biosimilars | 100 | 1 |
| Pipeline Products | 101 | 1 |
| Financial Performance | 101 | 1 |
| Hospira Inc | 102 | 1 |
| Approved Biosimilar Products: | 102 | 1 |
| Pipeline | 102 | 2 |
| Dr. Reddy s Laboratories | 104 | 1 |
| Approved Biosimilars | 105 | 1 |
| Biocon Ltd | 106 | 1 |
| Approved biosimilar products: | 107 | 1 |
| Pipeline | 107 | 1 |
| Biopartners | 108 | 1 |
| Approved Biosimilars | 109 | 1 |
| Watson Pharmaceuticals | 110 | 1 |
| Financial Performance | 110 | 1 |
| Pipeline | 111 | 1 |
| STADA Arzneimittel AG | 112 | 1 |
| Approved and Pipeline Biosimilar Products | 113 | 1 |
| Reliance Life Sciences | 114 | 1 |
| Approved Biosimilar products | 115 | 1 |
| Intas Biopharmaceuticals | 116 | 2 |
| Celltrion Inc. | 118 | 1 |
| Pipeline | 119 | 1 |
| 3SBio Inc. | 120 | 1 |
| Approved Biosimilars | 120 | 1 |
| Pipeline Products | 121 | 1 |
| Biosimilars Approval Pathways in the US and Europe Strategic Consolidations | 122 | 3 |
| M&A Deals | 122 | 1 |
| Pfizer Biocon Deal | 122 | 1 |
| Teva Acquired Ratiopharm | 122 | 1 |
| Watson Itero Deal | 122 | 1 |
| Biocon and Mylan Strategic Collaboration | 122 | 1 |
| Merck Acquired Insmed s Follow-On Biologics for $130m | 122 | 1 |
| Teva and Lonza JV Targets Biosimilars | 123 | 1 |
| GTC Enters Follow-On-Biologic Founder Development Collaboration with Ag Research | 123 | 1 |
| Apotex Intas Deal | 123 | 1 |
| Teva Acquires CoGenesys | 123 | 1 |
| R&D Licensing Deals | 124 | 1 |
| Innogene Seals Deal With CIMAB to Market Biosimilars | 124 | 1 |
| Abraxis Licenses Rights to Biosimilar from Indian Firm Biocon | 124 | 1 |
| Biosimilars Approval Pathways in the US and Europe Appendix | 125 | 6 |
| Market Definitions | 125 | 1 |
| Abbreviations | 126 | 2 |
| Research Methodology | 128 | 2 |
| Coverage | 128 | 1 |
| Secondary Research | 128 | 1 |
| Primary Research | 129 | 1 |
| Expert Panel Validation | 129 | 1 |
| Contact Us | 129 | 1 |
| Sources | 130 | 1 |
| Disclaimer | 130 | 1 |